Want to share experiences with LPR-3? DSFE launches a special interest group on LPR3. Read more
Upcoming events:
Information and material from previous meetings can be found here.
Theme “Pragmatic trials: academic, regulatory, and industry perspective”.
Whereas the traditional randomized controlled trial is designed to establish efficacy of a specific drug, i.e. the effect under ideal conditions, the pragmatic trial is designed to establish effectiveness, i.e. how well the drug works in everyday clinical practice. To present the topic from different angles, we have invited speakers from regulatory agencies, academia, and the industry including Mira G.P. Zuidgeest and Simon Skibsted.
Please sign up by sending an email to info@dsfe.dk, no later than October 20th. We hope as many of you as possible are able to participate and we are looking forward to see you!
The Danish Society for Pharmacoepidemiology is offering a one-day course on “Intermediate Methods in Pharmacoepidemiology”, on November 4th, 2021. The course is held online and is free of charge for DSFE members. The course focuses on ways to control for confounding including use of propensity scores, through active comparator new user designs, self-controlled design and the use of instrumental variable analysis. The course will close with a lecture on validation methods. We are fortunate that a number of very skilled researchers and excellent lecturers have accepted to teach the course.
To register, please send an email to info@dsfe.dk, no later than November 1th.
SOCIETY
The Danish Society for Pharmacoepidemiology’s purpose is to promote the development of pharmacoepidemiology in Denmark in order to contribute to the appropriate use of medicines.
EDUCATION
The Danish Society for Pharmacoepidemiology will seek to contribute to undergraduate and postgraduate education and information of relevant professionals on pharmacoepidemiology.
RESEARCH
The Danish Society for Pharmacoepidemiology will seek to expand Danish research internationally and participate in international cooperation to promote pharmacoepidemiology.